Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dowlais reports solid Q1, warns of US tariff-related impacts

(Sharecast News) - Dowlais Group said in an update on Thursday that trading in the first quarter was in line with expectations, but it warned that its full-year performance was now expected to come in at the lower end of guidance, citing weaker auto production forecasts and the delayed recovery of tariff-related costs. The FTSE 250 company said adjusted revenue for the quarter fell 2.5% year-on-year in constant currency to £1.3bn, as macroeconomic volatility and phasing in customer programmes weighed on volumes.

Reported revenue declined 3.9% after accounting for £19m of foreign exchange headwinds.

The group said its adjusted operating margin improved by 80 basis points to 6.6%, helped by restructuring and other performance initiatives.

In the automotive division, which generated £1bn in adjusted revenue, growth in ePowertrain and a strong contribution from the China joint venture were offset by a 6.6% decline in Driveline revenue.

The drop was attributed to adverse customer mix and timing effects, as older platform phase-outs were not yet fully replaced by new ramp-ups.

ePowertrain revenue rose 3.9%, while the group's China JV delivered 11% revenue growth, aided by one-off ePowertrain gains.

Powder metallurgy revenue meanwhile declined 5.7%, impacted by softer demand in Europe and North America.

While the business slightly outperformed the market in those regions, operating margin in the segment dropped 150 basis points to 8.3%, driven by reduced volumes.

Dowlais reiterated that it did not expect current US tariffs to have a material direct financial impact, noting its historical ability to recover cost increases through commercial actions.

However, the group acknowledged that tariffs had negatively affected consumer sentiment, with S&P now forecasting a 3.3% decline in 2025 light vehicle production ex-China and a 1.7% decline globally.

As a result, Dowlais said it now expected full-year performance to land at the low end of its guidance range, which calls for flat to mid-single digit revenue decline and an adjusted operating margin of 6.5% to 7%.

Free cash flow was also expected to be below the prior year due to weaker volumes and higher restructuring costs.

Management anticipated a stronger second half, with tariff cost recovery weighted towards that period.

"Performance in the quarter was in line with expectations, with the results reflecting our geographically diversified portfolio, continued focus on executing against our global footprint restructuring programmes and ongoing performance initiatives," said chief executive officer Liam Butterworth.

"Looking ahead, we expect to fully recover the direct impact of current tariffs, however, based on the latest industry forecast and continued market volatility, we now anticipate delivering towards the lower end of our full-year guidance for both adjusted revenue and margin.

"Our proposed combination with American Axle is progressing well and will create a stronger, more resilient business, better positioned to navigate the changing dynamics of the industry."

Dowlais said its interim results were scheduled for 7 August.

At 1002 BST, shares in Dowlais Group were up 3% at 64.38p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.